Lumiliximab

Drug Profile

Lumiliximab

Alternative Names: Anti-CD23 monoclonal antibody - IDEC; Gomiliximab; IDEC-152; PRIMATIZED anti-CD23; ST-152

Latest Information Update: 28 May 2010

Price : $50

At a glance

  • Originator Biogen Idec
  • Class Antiallergics; Monoclonal antibodies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; IgE receptor antagonists; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Chronic lymphocytic leukaemia

Highest Development Phases

  • Discontinued Allergic asthma; Allergic rhinitis; Chronic lymphocytic leukaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 May 2010 Discontinued - Phase-II for Chronic lymphocytic leukaemia in Australia (IV)
  • 28 May 2010 Discontinued - Phase-II for Chronic lymphocytic leukaemia in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top